CA-TALKDESK
4.6.2024 15:01:27 CEST | Business Wire | Press release
Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, is leading the charge to rid the world of bad CX with the launch of generative AI (GenAI)-powered Talkdesk Navigator and mood insights, today at Customer Contact Week Las Vegas 2024.
Harnessing the power of GenAI, Talkdesk is paving the way for hyper-personalized customer experiences that dynamically adjust content, offers, and recommendations based on each customer's unique profile, history, usage patterns, location, demographics, and even current emotional state. Talkdesk Navigator makes it simple to create new, as well as improve existing, customer journeys, providing brands with intuitive, conversational, and context-aware interaction orchestration. Mood insights, a feature of Talkdesk Interaction Analytics™, evaluates customers' emotional states throughout an interaction, speeding time to resolution and improving customer satisfaction.
Talkdesk Navigator provides GenAI-powered routing and is the first point of contact when customers engage with customer support or sales. It autonomously manages and prioritizes incoming inquiries based on real-time context. Using natural conversation, Talkdesk Navigator can understand customer requests and then automatically deliver the ideal experience for every customer, every time.
Customers simply tell Talkdesk Navigator what they need or want to accomplish, in their own words, without being forced into complex, rigid, and frustrating interactive voice response (IVR) menus. For administrators, Talkdesk Navigator eliminates the tedious setup and iterations required to build natural, efficient customer experiences. With no training required, it can understand naturally and initiate the most efficient path to resolution.
Talkdesk Interaction Analytics reviews customer conversations for topics and sentiment trends without setup. With GenAI, it detects emerging topics, uncovering valuable insights and opportunities—even the unexpected ones. The addition of mood insights allows contact centers to now capture the complexity of human feelings and provide emotional analysis at the beginning and end of the interaction—and the reason why those emotions may have changed. Agents can better support customers, and operational leaders can understand which behaviors to emphasize in order to improve agent performance
Traditional sentiment analysis generally lumps a customer’s emotional state into three broad categories—positive, negative, and neutral—and neglects the nuances of emotion that often change throughout the interaction. Powered by a large language model (LLM), the Talkdesk GenAI-powered mood insights captures feelings like gratitude, annoyance, and relief. By understanding the reason why customer emotions change during an interaction, contact centers can tailor their interactions and mitigate potential issues more precisely and accurately.
Talkdesk has been serving up practical AI in the contact center since 2018. Talkdesk Navigator and mood insights follow recent introductions of several other groundbreaking and industry-first GenAI innovations in CX from the company, including Talkdesk Ascend Connect, Talkdesk Autopilot for Banking, Talkdesk Autopilot for Retail, and Talkdesk Autopilot for Healthcare.
Supporting Quotes
Zeus Kerravala, founder and principal analyst of ZK Research, commented: “Generative AI has had a profound impact on how companies support and service their customers, and we’re really just beginning to see what’s possible. Talkdesk Navigator and mood insights are at the forefront of this new era of hyper-personalized customer experience that moves us away from hard-to-use interactive voice response systems toward a more natural, customized, and easier engagement with brands. This should be a natural progression for any company looking to transform the customer journey.”
Tiago Paiva, chief executive officer and founder of Talkdesk, said: "Generative AI has opened up new possibilities for CX and is rewriting the rules of customer engagement. Traditional personalization is no longer enough. Customers expect interactions tailored to their unique preferences and emotions. With Talkdesk Navigator and mood insights, we're empowering organizations to deliver hyper-personalized experiences with AI that drive deeper connections that foster lasting customer loyalty."
About Talkdesk
Talkdesk® is on a mission to rid the world of bad customer experience. With our cloud-native, generative AI-powered CX platform, purpose-built industry solutions, and extensible AI offerings, we empower enterprises in the cloud and on-premises to deliver exceptional customer experiences that make them more competitive, grow revenue, reduce costs, and provide operational efficiencies. With specialized workflows and integrations delivered out of the box for our Industry Experience Clouds, Talkdesk accelerates value for our customers faster and more simply than legacy or one-size-fits-all solutions.
Partnering with enterprises globally, we deliver continuous innovation and breakthrough results. Our commitment to reliability and security, paired with our track record of delivering on promises, sets us apart in the industry. Elevate customer experiences, streamline operations, and increase revenue with Talkdesk. Companies that love their customers use Talkdesk.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604367824/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
